DK2914627T3 - Anti-cd40-antistoffer og fremgangsmåder til anvendelse - Google Patents
Anti-cd40-antistoffer og fremgangsmåder til anvendelse Download PDFInfo
- Publication number
- DK2914627T3 DK2914627T3 DK13786884.0T DK13786884T DK2914627T3 DK 2914627 T3 DK2914627 T3 DK 2914627T3 DK 13786884 T DK13786884 T DK 13786884T DK 2914627 T3 DK2914627 T3 DK 2914627T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261720289P | 2012-10-30 | 2012-10-30 | |
| PCT/US2013/067583 WO2014070934A1 (en) | 2012-10-30 | 2013-10-30 | Anti-cd40 antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2914627T3 true DK2914627T3 (da) | 2021-07-12 |
Family
ID=49551838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13786884.0T DK2914627T3 (da) | 2012-10-30 | 2013-10-30 | Anti-cd40-antistoffer og fremgangsmåder til anvendelse |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US9676861B2 (da) |
| EP (2) | EP2914627B1 (da) |
| JP (5) | JP6693745B2 (da) |
| KR (1) | KR102270618B1 (da) |
| CN (3) | CN109265552A (da) |
| AU (2) | AU2013337903B2 (da) |
| CA (1) | CA2888763A1 (da) |
| DK (1) | DK2914627T3 (da) |
| ES (1) | ES2879552T3 (da) |
| HK (1) | HK1213581A1 (da) |
| NZ (1) | NZ707086A (da) |
| WO (1) | WO2014070934A1 (da) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102002104A (zh) | 2009-08-28 | 2011-04-06 | 江苏先声药物研究有限公司 | 一种抗vegf的单克隆抗体及含有该抗体的药物组合物 |
| US20140031250A1 (en) | 2010-10-07 | 2014-01-30 | David Tsai Ting | Biomarkers of Cancer |
| CN103635488B (zh) | 2011-04-29 | 2016-12-14 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
| AU2013337903B2 (en) | 2012-10-30 | 2018-08-16 | Apexigen, Inc. | Anti-CD40 antibodies and methods of use |
| EP3161159B1 (en) | 2014-06-25 | 2020-08-05 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
| CN105693845B (zh) * | 2014-11-24 | 2020-10-02 | 中国科学院上海营养与健康研究所 | 一种cd40胞外区的表达纯化及其用途 |
| AR104809A1 (es) | 2015-05-29 | 2017-08-16 | Abbvie Inc | Anticuerpos anti-cd40 y usos de los mismos |
| IL274572B2 (en) | 2015-07-16 | 2024-01-01 | Biolinerx Ltd | Compositions and methods for treating cancer |
| CN109069622A (zh) | 2015-09-30 | 2018-12-21 | 詹森生物科技公司 | 特异性结合人cd40的拮抗性抗体和使用方法 |
| CN116059344A (zh) | 2015-11-03 | 2023-05-05 | 詹森生物科技公司 | 特异性结合pd-1的抗体及其用途 |
| MX2018010672A (es) * | 2016-03-04 | 2019-05-27 | Univ Rockefeller | Anticuerpos para cumulo de diferenciación 40 (cd40) con actividad agonista mejorada. |
| CN109071665B (zh) | 2016-04-18 | 2022-11-01 | 塞德斯医疗公司 | 结合人cd40的激动性抗体及其用途 |
| EP3458485B1 (en) | 2016-05-19 | 2021-12-29 | The General Hospital Corporation | Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity |
| JP2019523221A (ja) | 2016-05-27 | 2019-08-22 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | 抗ｃｄ４０抗体とその使用 |
| CN109476747A (zh) | 2016-05-27 | 2019-03-15 | 艾伯维生物制药股份有限公司 | 结合免疫调节性蛋白和肿瘤抗原的双特异性结合蛋白 |
| FI3468997T3 (fi) | 2016-06-08 | 2023-10-31 | Xencor Inc | Igg4:ään liittyvien sairauksien hoito anti-cd19-vasta-aineilla, jotka ristisitoutuvat cd32b:een |
| EP3470424A4 (en) | 2016-06-08 | 2020-03-04 | Shanghai Jiaotong University School of Medicine | CONSTANT HEAVY CHAIN REGION SEQUENCE OF ANTIBODIES TO IMPROVE THE ACTIVITY OF AGONIST ANTIBODIES |
| CA3026477A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 antibodies |
| KR20240017129A (ko) | 2016-07-14 | 2024-02-06 | 젠맵 에이/에스 | Cd40 및 cd137에 대한 다중특이적 항체 |
| KR102554331B1 (ko) | 2016-08-12 | 2023-07-10 | 얀센 바이오테크 인코포레이티드 | 향상된 효능적 활성을 갖는 Fc 조작된 항-TNFR 수퍼패밀리 구성원 항체 및 그의 사용 방법 |
| JP7178342B2 (ja) | 2016-08-12 | 2022-11-25 | ヤンセン バイオテツク，インコーポレーテツド | アゴニズム及びエフェクター機能が増強した改変抗体、及び他のＦｃドメイン含有分子 |
| AU2017353852A1 (en) * | 2016-11-02 | 2019-05-23 | Apexigen, Inc. | Anti-CD40 antibodies in combination and methods of use |
| WO2018089688A1 (en) | 2016-11-09 | 2018-05-17 | Jinjun Shi | Restoration of tumor suppression using mrna-based delivery system |
| CN110382541A (zh) * | 2017-03-29 | 2019-10-25 | 葛莱高托普有限公司 | 人源化抗cd40抗体 |
| TWI788340B (zh) * | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| KR20200012920A (ko) | 2017-06-01 | 2020-02-05 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 항-cd40 항체, 이의 항원 결합 단편 및 이의 의학적 용도 |
| WO2018233607A1 (en) * | 2017-06-19 | 2018-12-27 | Beijing Biocytogen Co., Ltd | NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH HUMAN OR CHIMERIC CD40 |
| CN109136274B (zh) | 2017-06-19 | 2021-04-23 | 百奥赛图江苏基因生物技术有限公司 | 人源化cd40基因改造动物模型的制备方法及应用 |
| CN109384845B (zh) * | 2017-08-14 | 2022-06-21 | 中国科学院上海营养与健康研究所 | 一种cd40单克隆抗体、其制备方法及其应用 |
| WO2019143837A1 (en) | 2018-01-17 | 2019-07-25 | Apexigen, Inc. | Anti-pd-l1 antibodies and methods of use |
| EP4317972A3 (en) | 2018-02-06 | 2024-03-13 | The General Hospital Corporation | Repeat rna as biomarkers of tumor immune response |
| CN112512572B (zh) * | 2018-04-20 | 2024-12-10 | 礼进生物医药科技（上海）有限公司 | 抗cd40抗体及其用途 |
| CN112638375A (zh) | 2018-06-15 | 2021-04-09 | 旗舰创业创新五公司 | 通过后细胞信号传导因子的调节来增加免疫活性 |
| MX2021000688A (es) | 2018-07-20 | 2021-03-25 | Eucure Beijing Biopharma Co Ltd | Anticuerpos anti-cd40 y usos de los mismos. |
| AR117091A1 (es) * | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| CA3119865A1 (en) | 2018-11-23 | 2020-05-28 | Strike Pharma Ab | Bi-specific conjugates |
| CA3121291A1 (en) | 2018-11-30 | 2020-06-04 | Jiangsu Hengrui Medicine Co., Ltd. | Cd40 antibody pharmaceutical composition and use thereof |
| JP2022509156A (ja) | 2018-11-30 | 2022-01-20 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 |
| CN109678959B (zh) * | 2019-02-22 | 2020-12-08 | 北京免疫方舟医药科技有限公司 | 抗cd40抗体及其应用 |
| CN111454361B (zh) * | 2019-03-04 | 2021-03-02 | 北京天广实生物技术股份有限公司 | 与cd40结合的抗体及其用途 |
| US10570210B1 (en) | 2019-03-04 | 2020-02-25 | Beijing Mabworks Biotech Co.Ltd | Antibodies binding CD40 and uses thereof |
| SG11202111188VA (en) * | 2019-04-10 | 2021-11-29 | Univ Nankai | Anti-cd40 antibody and use thereof |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| US20220370418A1 (en) | 2019-09-09 | 2022-11-24 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
| AU2019465294A1 (en) * | 2019-09-11 | 2022-03-24 | Novartis Ag | A method for preventing human virus associated disorders in patients |
| JP2022553108A (ja) * | 2019-10-23 | 2022-12-21 | リビジェン バイオファーマ ホールディングス リミテッド | 抗ｃｄ４０結合分子およびそのようなものを含む二重特異性抗体 |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| IL294608A (en) | 2020-01-10 | 2022-09-01 | Brigham & Womens Hospital Inc | Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer |
| GB202008003D0 (en) | 2020-05-28 | 2020-07-15 | Quine Medical Ab | Anti-CD40 antibody |
| WO2022006179A1 (en) | 2020-06-29 | 2022-01-06 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| WO2022002065A1 (zh) * | 2020-06-30 | 2022-01-06 | 百奥泰生物制药股份有限公司 | 抗cd40抗体或抗原结合片段及其应用 |
| AU2022246895A1 (en) | 2021-03-31 | 2023-10-19 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| AU2022303363A1 (en) | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| US20240398942A1 (en) * | 2021-09-26 | 2024-12-05 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Use of anti-cd40 antibody |
| TWI863317B (zh) | 2022-05-31 | 2024-11-21 | 大陸商明濟生物製藥(北京)有限公司 | 抗cd40抗體和抗pd-l1×cd40雙特異抗體及其應用 |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
Family Cites Families (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
| US4237224A (en) | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5247069A (en) | 1986-06-13 | 1993-09-21 | Oncogen | Ligands and methods for augmenting B-cell proliferation |
| US5182368A (en) | 1986-06-13 | 1993-01-26 | Ledbetter Jeffrey A | Ligands and methods for augmenting B-cell proliferation |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| WO1995009653A1 (en) | 1993-10-01 | 1995-04-13 | Immunex Corporation | Antibodies to cd40 |
| ATE267607T1 (de) * | 1993-12-23 | 2004-06-15 | Immunex Corp | Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| GB9425060D0 (en) | 1994-12-13 | 1995-02-08 | Univ Birmingham | Carcinoma treatment |
| US5675063A (en) | 1995-02-28 | 1997-10-07 | Loyola University Of Chicago | Immortalized rabbit hybridoma fusion partner |
| AU699291B2 (en) | 1995-03-01 | 1998-11-26 | Immunex Corporation | Method for stimulating an immune response |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| EP1033406A4 (en) * | 1997-10-27 | 2005-03-09 | Sumitomo Electric Industries | INDUCER FOR THE PRODUCTION OF ANTIGEN-SPECIFIC ANTIBODY, EXPRESSION VECTOR CONTAINING THE GENE REQUIRED THEREFOR, AND METHOD FOR INDUCING THE PRODUCTION OF THE ANTIGEN-SPECIFIC ANTIBODY |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| KR100301796B1 (ko) * | 1998-10-01 | 2001-09-06 | 성재갑 | 면역억제능이 있는 항-씨디40 리간드 모노클로날 항체 |
| US6680176B2 (en) | 1999-05-17 | 2004-01-20 | The United States Of America, As Represented By The Department Of Health And Human Services | Identification of candidate ligands which modulate antigen presenting cells |
| US20030118588A1 (en) | 1999-05-22 | 2003-06-26 | Linda Diehl | Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40 |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| MXPA02007473A (es) | 2000-02-01 | 2003-09-22 | Tanox Inc | Moleculas activadoras de celulas presentadoras de antigenos (apc) que se unen a cd40. |
| BR0110190A (pt) | 2000-04-19 | 2003-12-30 | Tanox Inc | Antagonistas de cd40 para uso em tratamento de psorìase e outras condições inflamatórias de pele |
| US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| ATE553131T1 (de) | 2000-05-08 | 2012-04-15 | Celldex Res Corp | Humane monoklonale antikörper gegen dendritische zellen |
| CN101508734A (zh) | 2001-04-27 | 2009-08-19 | 协和发酵麒麟株式会社 | 抗cd40单克隆抗体 |
| JP4025881B2 (ja) * | 2001-04-27 | 2007-12-26 | キリンファーマ株式会社 | 抗ｃｄ４０モノクローナル抗体 |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040110226A1 (en) * | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20080199471A1 (en) | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| ES2349777T3 (es) * | 2003-01-22 | 2011-01-11 | Glycart Biotechnology Ag | Constructos de fusión y uso de los mismos para producir anticuerpos con mayor afinidad de unión al receptor de fc y función efectora. |
| DK1682180T3 (da) * | 2003-11-04 | 2010-01-11 | Novartis Vaccines & Diagnostic | Monoklonale antagonist-anti-CD40-antistoffer og fremgangsmåder til anvendelse deraf |
| AU2004297616B2 (en) | 2003-12-04 | 2008-12-18 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| US20050136055A1 (en) | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
| DK1707627T3 (da) * | 2003-12-25 | 2012-12-17 | Kyowa Hakko Kirin Co Ltd | Antagonistisk anti-CD40-antistofmutant. |
| BR122018016031B8 (pt) | 2004-08-04 | 2021-07-27 | Applied Molecular Evolution Inc | processo para produzir um anticorpo monoclonal variante com resposta de adcc realçada |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
| WO2006079372A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| US20060257359A1 (en) | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
| WO2006105338A2 (en) | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
| ES2429564T3 (es) | 2005-05-18 | 2013-11-15 | Novartis Ag | Procedimientos para el diagnóstico y tratamiento de enfermedades que tienen un componente autoinmune y/o inflamatorio |
| EP1894012A2 (en) | 2005-05-18 | 2008-03-05 | Novartis AG | Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling |
| AU2006249305B2 (en) | 2005-05-26 | 2012-10-18 | Genentech, Inc. | Humanized anti-CD40 antibodies and their methods of use |
| US7429487B2 (en) | 2005-07-05 | 2008-09-30 | Epitomics, Inc. | Fusion partner for production of monoclonal rabbit antibodies |
| CA2628105A1 (en) | 2005-11-01 | 2007-05-10 | Novartis Ag | Uses of anti-cd40 antibodies |
| CN101351478A (zh) | 2005-11-01 | 2009-01-21 | 诺华有限公司 | 抗cd40抗体的应用 |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 １가 항체 및 그의 제조 방법 |
| CA2632698A1 (en) * | 2005-12-09 | 2007-07-05 | Seattle Genetics, Inc. | Methods of using cd40 binding agents |
| JP5357778B2 (ja) * | 2007-01-23 | 2013-12-04 | ゼンコー・インコーポレイテッド | 最適化ｃｄ４０抗体および前記を使用する方法 |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US20090238825A1 (en) | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| CN101868477A (zh) | 2007-05-21 | 2010-10-20 | 奥尔德生物制药公司 | 新型兔抗体人源化方法和人源化的兔抗体 |
| EP2708557A1 (en) | 2007-05-30 | 2014-03-19 | Xencor, Inc. | Method and compositions for inhibiting CD32B expressing cells |
| US8551485B2 (en) | 2008-01-23 | 2013-10-08 | Xencor, Inc. | Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cells |
| NZ590628A (en) | 2008-07-16 | 2012-03-30 | Baylor Res Inst | Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
| AU2009286247A1 (en) | 2008-08-29 | 2010-03-04 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Delivery of a CD40 agonist to a tumor draining lymph node of a subject |
| ES2650267T3 (es) | 2008-12-05 | 2018-01-17 | Als Therapy Development Institute | Método para el tratamiento de enfermedades neurodegenerativas |
| PT2406286T (pt) | 2009-03-10 | 2016-08-19 | Baylor Res Inst | Anticorpos anti-cd40 e seus usos |
| US9617600B2 (en) | 2009-04-18 | 2017-04-11 | Genentech, Inc. | Methods for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies |
| JP5694921B2 (ja) | 2009-04-20 | 2015-04-01 | 協和発酵キリン株式会社 | アミノ酸変異が導入されたＩｇＧ２を有する抗体 |
| CN102971340A (zh) * | 2010-03-29 | 2013-03-13 | 酵活有限公司 | 具有增强的或抑制的效应子功能的抗体 |
| CA2794332C (en) | 2010-03-31 | 2019-05-14 | Boehringer Ingelheim International Gmbh | Anti-cd40 antibodies |
| EP2600878A4 (en) | 2010-08-04 | 2014-06-11 | Univ Duke | REGULATORY B-CELLS AND ITS USES |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| CA2824278C (en) | 2010-12-20 | 2022-09-20 | The Rockefeller University | Modulating agonistic tnfr antibodies |
| ME03071B (me) * | 2011-04-21 | 2019-01-20 | Bristol Myers Squibb Co | Polipeptidi antitela koji antagonizuju cd40 |
| CN103635488B (zh) | 2011-04-29 | 2016-12-14 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
| AU2013337903B2 (en) | 2012-10-30 | 2018-08-16 | Apexigen, Inc. | Anti-CD40 antibodies and methods of use |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2013
- 2013-10-30 AU AU2013337903A patent/AU2013337903B2/en active Active
- 2013-10-30 CA CA2888763A patent/CA2888763A1/en active Pending
- 2013-10-30 CN CN201811214473.6A patent/CN109265552A/zh active Pending
- 2013-10-30 US US14/067,770 patent/US9676861B2/en active Active
- 2013-10-30 CN CN201811214790.8A patent/CN110066335B/zh active Active
- 2013-10-30 ES ES13786884T patent/ES2879552T3/es active Active
- 2013-10-30 EP EP13786884.0A patent/EP2914627B1/en active Active
- 2013-10-30 DK DK13786884.0T patent/DK2914627T3/da active
- 2013-10-30 KR KR1020157013665A patent/KR102270618B1/ko active IP Right Grant
- 2013-10-30 CN CN201380068690.8A patent/CN104918957B/zh active Active
- 2013-10-30 JP JP2015539949A patent/JP6693745B2/ja active Active
- 2013-10-30 NZ NZ707086A patent/NZ707086A/en unknown
- 2013-10-30 WO PCT/US2013/067583 patent/WO2014070934A1/en active Application Filing
- 2013-10-30 EP EP21166914.8A patent/EP3925977A1/en active Pending
-
2016
- 2016-02-12 HK HK16101574.4A patent/HK1213581A1/zh unknown
-
2017
- 2017-05-12 US US15/594,367 patent/US9994640B2/en active Active
-
2018
- 2018-03-13 US US15/920,197 patent/US20180273630A1/en not_active Abandoned
- 2018-08-06 JP JP2018147573A patent/JP2018166522A/ja not_active Withdrawn
- 2018-11-02 AU AU2018256638A patent/AU2018256638B2/en active Active
-
2020
- 2020-08-21 JP JP2020139887A patent/JP2020195388A/ja not_active Withdrawn
-
2021
- 2021-04-15 US US17/231,483 patent/US20220049006A1/en not_active Abandoned
-
2022
- 2022-10-11 JP JP2022163062A patent/JP7482184B2/ja active Active
-
2023
- 2023-03-13 US US18/182,827 patent/US20230406948A1/en active Pending
-
2024
- 2024-04-26 JP JP2024072388A patent/JP2024096245A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2914627T3 (da) | Anti-cd40-antistoffer og fremgangsmåder til anvendelse | |
| IL280155A (en) | Anti- SIGLEC-8 antibodies and methods of using them | |
| DK3083689T3 (da) | Anti-CD3-antistoffer og fremgangsmåder til anvendelse | |
| DK2675827T3 (da) | Hidtil ukendte modulatorer og fremgangsmåder til anvendelse | |
| DK2900657T3 (da) | Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse | |
| DK3556774T3 (da) | Anti-CD40-antistoffer og anvendelser deraf | |
| ZA201603308B (en) | Novel anti-claudin antibodies and methods of use | |
| DK2961831T3 (da) | Sammensætninger og fremgangsmåder til immunterapi | |
| DK2929031T5 (da) | Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf | |
| HK1212256A1 (en) | Anti-mcam antibodies and associated methods of use -mcam | |
| IL245946A0 (en) | Anti-dpep3 antibodies and methods of use | |
| ME02928B (me) | Dll3 modulatori i metode upotrebe | |
| DK2914291T3 (da) | Anti-komplement-c1s-antistoffer og anvendelser deraf | |
| DK3086807T3 (da) | Antistoffer og fremgangsmåder til anvendelse | |
| HUE051982T2 (hu) | Anti-alfa-szinuklein antitestek és alkalmazási eljárások | |
| DK2683731T3 (da) | C4-monomethyl-triterpenoidderivater og fremgangsmåder til anvendelse deraf | |
| DK2806892T3 (da) | Kombineret terapeutisk anvendelse af antistoffer og endoglycosidaser | |
| IL238227A0 (en) | Antibodies against c16orf54 and uses thereof | |
| ZA201404675B (en) | Anti-lrp5 antibodies and methods of use | |
| EP2734234A4 (en) | ANTI-CXCR4 ANTIBODIES AND METHOD OF USE THEREOF | |
| HK1225612A1 (zh) | 抗ly6e抗體及使用方法 | |
| DK3453723T3 (da) | Anti-ASIC1-antistoffer og anvendelser deraf | |
| HK1209432A1 (en) | Anti-jagged antibodies and methods of use | |
| DK2882863T3 (da) | System og fremgangsmåde til kvantitativ billeddannelse af mitokondriekompleks 1 | |
| DK2920204T3 (da) | Streptavidinmuteiner og fremgangsmåder til anvendelse deraf |